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Abstract
Background: The effect of thiopurine immunomodulators on health-related quality of life (HRQoL) in patients with
inflammatory bowel disease (IBD) has been controversial. The aims were to evaluate the HRQoL in patients with
IBD treated with thiopurines and assess the short- and long-term impacts of the treatment on HRQoL.
Methods: Ninety-two consecutive patients who started treatment with thiopurines were prospectively included.
Evaluation of HRQoL was performed at months 0, 6, and 12 using two questionnaires, the Short-Form Health
Survey (SF-36) and the Inflammatory Bowel Disease Questionnaire (IBDQ).
Results: Baseline score of IBDQ was 4,6, range (2,31-6,84), with an impairment of the five dimensions of HRQoL
compared with inactive patients. Results obtained in 8 dimensions of SF-36 showed worse HRQoL than Spanish
general population. At 6 months patients had a significant improvement in overall IBDQ score -5,8 (1,58 -6,97)- and
also in all IBDQ dimensions. All the 8 dimensions of SF-36 obtained a significant improvement. At twelve months
score of IBDQ was 6,1, range (2,7-6,98), with improvement in all dimensions compared with baseline and 6 months.
SF-36 showed a similar significant improvement in all subscales.
Conclusions: Thiopurine immunomodulators alone or with other treatments have a positive and long lasting
impact on HRQoL of IBD patients.
Background
The inflammatory bowel diseases (IBD) Crohn’s disease
(CD) and ulcerative colitis (UC) are chronic relapsing
conditions of unknown etiology [1]. The young age of
onset and the morbidity associated with these diseases
and their therapies affect patients, not only physically
but also through limitations in social, educational, pro-
fessional and emotional activities. It is well documented
that IBD patients have an impaired perception of their
health-related quality of life (HRQoL) compared with an
age- and sex-matched population [2-8].
Although controlling disease activity is of prime
importance in patient well-being, conventional morpho-
logical measures and activity indices do not assess the
subjective perception of health and the overall impact of
the disease on patients’ lives [9]. For these reasons, it is
currently accepted that the goals of therapy should be
to control symptoms, reduce complications, minimize
treatment toxicity and improve quality of life [10].
The efficacy of thiopurines in the scenarios in which
they are prescribed–either to induce or to maintain
remission in both UC and CD–is well proven [11-14]. It
is recognized that in both CD and UC, HRQoL is
strongly linked to an individual’s current level of symp-
toms [15,16]. The achievement and maintenance of
remission should be accompanied by an increase in
HRQoL; however, other factors could influence the
effects of any treatment on HRQoL, such as patient psy-
chosocial characteristics, outcome expectancies, fear of
side effects, and attitudes and beliefs toward the treat-
ment. Most of the useful treatments in IBD, such as
mesalazine, budesonide, cyclosporine, infliximab, natali-
zumab, leukocyte apheresis and surgery have proven to
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sive drugs on HRQoL have been controversial. Some
authors have reported a worse HRQoL among
azathioprine users while others found better HRQoL
among thiopurine-treated patients [27,28]. A recent
case-control study comparing the HRQoL of CD
patients in stable remission with thiopurine immunomo-
dulators with matched healthy controls showed that
treatment restores HRQoL and psychological well-being
to normal levels [29]. In consequence, the thiopurines
may have a positive impact on HRQoL, mainly in
patients with inactive disease; however, several issues
should be addressed. First, information is scarce, the
pattern of HRQoL of the patients before starting thio-
purines is not known, and there are no published pro-
spective studies analyzing the impact of thiopurines on
different dimensions of HRQoL. Second, even less infor-
mation is available in UC patients, and third, the differ-
ent scenarios where thiopurines are prescribed could
alter the benefits of thiopurine treatment.
Knowledge of the main affected dimensions and the
effect of thiopurines on HRQoL would be of consider-
able help to evaluate medical treatment and quality of
care, to conduct economical analysis, and to develop
guidelines for clinical practice.
Therefore, the main objective of this study was to
evaluate the quality of life in patients with inflammatory
bowel disease treated with thiopurines and to assess the
short- and long-term impacts of the treatment on differ-
ent dimensions of quality of life. Additionally, we ana-
lyzed the relationships between clinical and biological
variables with HRQoL.
Methods
Study Population
Participants were recruited from a single Spanish hospi-
tal. The diagnoses of IBD were made according to the
Lennard-Jones criteria [30] and patients were classified
in accordance with the Montreal classification [31]. In
patients with CD, age at diagnosis, lesion location
(ileum, colon, ileum and colon or upper gastrointestinal
tract), disease behavior (stricturing, penetrating or non-
stricturing and nonpenetrating) and the presence of
perianal disease were recordedt oc l a s s i f yt h es u b j e c t s .
UC was classified into three subgroups: ulcerative proc-
titis; left-sided UC (distal UC); and extensive UC
(pancolitis).
We prospectively and consecutively studied all adult
subjects with IBD either attending as outpatients or dur-
ing hospital admission who started treatment with thio-
purines. The indications to initiate thiopurines in both
CD and UC were steroid dependency, induction of
remission, and maintenance treatment after a severe
flare. In patients with CD, thiopurines were additionally
used to treat perianal disease, to treat extensive disease,
and to prevent postsurgical recurrence.
All patients who underwent surgery were endoscopi-
cally evaluated after 12 months, recurrence in the neo-
terminal ileum was defined by a Rutgeerts score > = 1.
In case of recurrence, patients were started with
Azathioprine. The patients who started thiopurines
immediately after surgery were not eligible for the study.
Induction treatment with infliximab, at three doses of
5 mg/Kg, was allowed at the beginning of the study,
those patients who received maintenance treatment with
infliximab were excluded. The treatment was considered
as failure if the patient required infliximab or surgery
during the follow up.
Treatment
All patients were treated initially with azathioprine.
Although the enzyme activity of thiopurine methyltrans-
ferase (TPMT) was measured at the beginning of treat-
ment, AZA was started at 50 mg daily and was
increased to a target dose of 2.5 mg/kg within the first
month of follow up [32].
HRQoL Assessment
Prospective evaluation of HRQoL was performed at
months 0, 6, and 12 using two questionnaires, the Medi-
cal Outcomes Study 36-Item Short-Form Health Survey
(SF-36) and the Inflammatory Bowel Disease Question-
naire (IBDQ). The SF-36 is a generic questionnaire con-
taining 36 items [33]. Thirty-five of the items are
grouped into eight multi-item scales. The eight domains
of the SF-36 are as follows: physical function (10 items);
social function (two items); role limitations due to phy-
sical problems (four items); role limitations due to emo-
tional problems (three items); energy/vitality (four
items); mental health (five items); bodily pain (two
items); and general health perception (five items). In
addition, it contains a one-item measure of self-evalu-
ated change in health status (health transition) over the
previous year. For each question, the raw score was
coded and transformed into a percentage on a scale of 0
to 100, with 0 indicating the least favorable possible
health status and 100 indicating the most favorable. The
questionnaire has been translated into Spanish and vali-
dated [34]. The disease-specific questionnaire used, the
I B D Q ,w a st h e3 6 - i t e mv e r s i o nb yL o v ee ta l[ 2 ] ,as e l f -
administered questionnaire that has been previously
validated for use in Spain [35]. The 36 items are
grouped into five domains of health: bowel symptoms;
systemic symptoms; functional impairment; social
impairment; and emotional function. Responses are
scored on a 7-point Likert scale, in which 7 corresponds
to the highest level of functioning. The instrument pro-
duces five dimension scores and an overall IBDQ score
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HRQoL.
Assessment of Clinical Activity and Definitions of
Remission
Disease activity was assessed with the Crohn’sD i s e a s e
Activity Index (CDAI) in patients with CD and with
Mayo Clinic Score or the Disease Activity Index (CAI)
in patients with UC [36,37]. Eight variables determine
the CDAI score: the number of liquid stools; the extent
of abdominal pain; general well-being; the occurrence of
extraintestinal symptoms; the need for antidiarrheal
drugs; the presence of abdominal masses; hematocrit;
and body weight. In order to calculate the CDAI, the
patient completed a symptom diary for the seven days
before each visit. Remission was defined as defined by a
CDAI score < 150. The Mayo Score consists of four
items: stool frequency; rectal bleeding; findings of flex-
ible proctosigmoidoscopy; and the Physician Global
Assessment. Scores range from 0 to 12 points. Complete
response (remission) is defined as complete resolution
of (1) stool frequency (normal stool frequency), (2) rec-
tal bleeding (no rectal bleeding), and (3) patient’sf u n c -
tional assessment score (generally well). If colonoscopy
was available, normal endoscopy findings were also
required. The patients should be free of steroids to be
considered in remission.
Study Design and Follow up
Patients were enrolled prospectively. Demographic data
were recorded during the first visit. Blood samples were
taken before starting on AZA, and TPMT activity was
measured. Patients were clinically evaluated at baseline,
at two, four and 12 weeks, and then every three months
until the end of the study. HRQoL assessment was per-
formed at the beginning and after six and 12 months of
therapy. Patients were also evaluated throughout the
s t u d yp e r i o dw h e n e v e rt h e yh a dam e d i c a lp r o b l e m .A t
each visit, a complete physical exam was performed and
patients were asked about symptoms and any systemic
manifestations of the disease or its treatment. Scores of
activity were calculated. Data on the use of steroids and
other concomitant treatments were obtained. Those
patients who discontinued their medication because of
adverse events or reactions were followed in the same
way as those who continued to receive therapy. In cases
of treatment failure, HRQoL assessment was performed
before new treatment was administered.
Statistical Analysis
Descriptive analysis of continuous variables is presented
as median and range and as counts (%) for categorical
data. Data were tested for a normal distribution: the nat-
ural logarithms of variables were used to reduce the
heterogeneity of variance if necessary. Repeated mea-
sures one-way ANOVA corrected with the Holm-Bon-
ferroni method was performed to explore differences in
the HRQoL values along the study. To A two-sided P
value of less than 0.05 was considered statistically
significant.
To aid interpretation and comparison, the magnitude
of differences was also expressed as an effect size (the
differences in scores divided by the standard deviation
for the reference group) [38]. We applied the generally
agreed thresholds (0.2, 0.5, and 0.8 respectively) for
‘small’, ‘moderate’ and ‘large’ effect sizes [39]. When the
SF-36 was used, for the individual scales a change of ten
or more points was considered a minimum important
difference [40]. In case of IBDQ-36 questionnaire an
absolute change of 0.5 points has been used to define a
minimum clinically important difference [41].
To determine whether there are factors at baseline
that can predict HRQoL at six months and one year,
multiple regression analysis taking the global score of
the IBDQ-36 as the dependent variable was performed.
The analysis was performed separately for UC and CD.
Ethical Considerations
The local research ethics committee (Comité Ético de
Investigación Biomédica de Hospital Universitario “La
Fe”) approved the study. Investigators fully explained
the details of the study, made sure that the volunteer
understood the information, and allowed the patient to
freely decide if they wish to participate in the study.
Afterwards the patient signed the informed consent
document.
Results
Study Patients
Ninety-two consecutive outpatients and inpatients who
started thiopurine immunomodulators were prospec-
tively included, 68 (74%) with CD and 24 (26%) with
U C .A l lp a t i e n t sh a dam i n i m u mf o l l o wu po fs i x
months and 74 patients had 12 months of follow up (18
patients had a follow-up period of between six and 12
months). Five and 10 patients left the study before six
and 12 months, respectively. Mean TPMT levels were
19.7 (SD 4.63), range (6.6-35.7): consequently, the target
dose was 2.5 mg/Kg in all patients. Twelve (13%)
patients had gastrointestinal intolerance to azathioprine
and in these patients; 6-mercaptopurine treatment was
attempted. Of these patients, seven ceased this thiopur-
ine treatment because of toxicity. Demographic charac-
teristics are listed in Table 1, and the indications for
treatment, disease classification, concomitant treatment
and other disease-related factors are listed in Table 2.
Seven patients (8%) had other comorbilities: 3 with dia-
betes mellitus, 3 with chronic HCV infection and one
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these diseases during the follow-up.
Basal Assessment
Basal median IBDQ score was 4.98 (range 2.31-6.88) and
was higher in patients with CD (4.99, range 2.37-6.84)
than in patients with UC (4.56, range 2.31-6.88), but
without statistical significance. The HRQoL determined
with the IBQQ showed a significant (greater than 0,5 in
a 7 point likert scale) impairment of all five dimensions
when compared with inactive inflammatory bowel dis-
ease Spanish patients. Results obtained for the five
dimensions of the HRQoL assessed by the IBDQ and
the eight dimensions analyzed by the SF-36 are shown
in Table 3 for patients with CD and in Table 4 for those
with UC.
The HRQoL determined with the SF-36 showed a sig-
nificant impairment of all eight dimensions when com-
pared with the general Spanish population. A
comparison of the SF-36 dimensions with the Spanish
population is shown in Fig. 1.
The basal IBDQ scores were significantly correlated
with CDAI (r = -0.56, P = 0.001), number of previous
admissions (r = -0.25, P = 0.02), steroid dosage at the
beginning of treatment (r = -0.50, P = 0.001), serum
albumin (r = 0.29, P = 0.02) and leukocyte count (r =
-0.26, P = 0.03). No significant correlation was seen
with age, gender, duration of illness, Mayo Score index,
platelet count, sedimentationr a t eo rw i t hf i b r i n o g e no r
CRP levels. Additionally, those patients who were on
steroids, hospitalized at the beginning of treatment, with
the indication of induction of remission or maintenance
after severe flare-up had significantly worse IBDQ
scores. Other variables studied, such as the type of dis-
ease, smoking status, previous surgery or presence of
perianal disease, did not have any significant influence
on basal IBDQ scores. For CD patients, in the multivari-
ate analysis, once adjusted fors e x ,a g e ,d u r a t i o no fd i s -
ease, number of previous admissions, previous surgery,
presence of perianal disease and concomitant treatment
at the beginning, only the CDAI and the use of steroids
were associated with the basal IBDQ score. No variable
was associated with the basal IBDQ score in UC
patients.
Six-month Assessment
After six months, five of the initial 92 patients were lost
to follow up, thus only 87patients were available to
complete the questionnaires. At this point, 54 patients–
59% as per intention to treat and 61% per protocol–
were in clinical remission and free of steroids. The
Table 1 Socio-demographic characteristics of patients
included.
Crohn’s disease Ulcerative colitis
Number 68 24
Age (years) 35 (16-70) 38 (16-67)
Sex (male/female) 37/31 11/13
Smoking status
Smoker 32 (47%) 4 (16%)
Ex-smoker 13 (19%) 4 (16%)
Nonsmoker 23 (34%) 16 (67%)
Marital status
Married 34 (50%) 6 (25%)
Single 29 (43%) 16 (67%)
Separated/divorced 5 (7%) 1 (4%)
Widowed - 1 (4%)
Results are expressed as medians and range or absolute value and
percentage.
Table 2 Clinical characteristics of patients included.
Crohn’s
disease
Ulcerative
colitis
Number 68 24
Disease duration (months) 27 (0-268) 11 (1-188)
Outpatients 61 (90%) 16 (67%)
Previous hospitalizations 2 (0-14) 2 (0-6)
Previous resective surgery 33 (49%) -
Localization
L1: Terminal ileum 28 (41%)
L2: Colon 21 (31%)
L3: Ileocolon 15 (22%)
L4: Upper gastrointestinal 4 (6%)
E1: Ulcerative proctitis 2 (8%)
E2: Left-sided Ulcerative
colitis
7 (29%)
E3: Extensive Ulcerative
colitis
15 (63%)
Behavior
B1: inflammatory 27 (40%)
B2: stricturing 26 (38%)
B3: penetrating 15 (22%)
Perianal disease 24 (35%) 1 (4%)
Indication of treatment
Steroid dependence 24 (35%) 15 (62%)
Induction of remission 10 (15%) 5 (21%)
Maintenance after severe
flare
1 (1%) 4 (17%)
Fistulizing disease 8 (12%) -
Prevention of recurrence 21 (31%) -
Extensive disease 4 (6%) -
Concomitant treatment
Steroids 35 (52%) 17 (71%)
Infliximab 8 (12%) -
Antibiotics 18 (27%) 1 (4%)
Mesalamine 2 (3%) 5 (21%)
Topical treatment 1 (2%) 19 (79%)
Results are expressed as medians and range or absolute value and
percentage.
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Compared with baseline, 63 (68%) patients’ scores
improved: the mean increase in IBDQ (ΔIBDQ) was
0.86 (SD 1.4; range -3.42 to 3.81), with an effect size of
0.68.
Differences from baseline in the five dimensions of
HRQoL analyzed by the IBDQ and the eight dimensions
assessed by the SF-36 are shown in Tables 3 and 4.
After six months of treatment with thiopurines, all
dimensions of the specific questionnaire (IBDQ)
improved significantly compared with baseline. HRQoL,
as assessed with the SF-36, showed a significant
improvement in all dimensions with the exception of
physical functioning and general health. This improve-
ment was independent of gender, age and type of the
disease except in mental health domain; in this subscale
men had a significant higher score. Despite the improve-
ment, all eight dimensions remained poorer than the
reference values of the Spanish general population, as
can be seen in Fig. 1.
Among the CD patients, the ΔIBDQ was significantly
poorer in those patients who had had previous surgery
Table 3 Health-related quality of life at baseline, six and at 12 months in Crohn’s disease patients.
Basal 6
th month 12
th month Trend p values (*) Differences 0 and 6
th month Differences 0 and 12
th month
Mean (SD) Mean (SD) Mean (SD) L Q Mean (CI 95%) ES Mean (CI 95%) ES
IBDQ:
Bowel 5,0 (0,9) 5,7 (1,1) 6,0 (1,1) 0,01 0,06 0,7 (0,4-1,0) 1,1 0,92 (0,6-1,3) 1,0
Systemic 4,4 (1,3) 5,1 (1,3) 5,4 (1,5) 0,01 0,01 0,7 (0,3-1,1) 0,5 1,0 (0,5-1,5) 0,8
Emotional 4,6 (1,2) 5,6 (1,0) 5,8 (1,2) 0,01 0,01 1,0 (0,7-1,4) 0,8 1,2 (0,8-1,6) 1,0
Social 5,1 (1,6) 6,0 (1,2) 6,2 (1,2) 0,01 0,12 0,9 (0,5- 1,3) 0,6 1,0 (0,5-1,6) 0,8
Functional 4,6 (1,5) 5,7 (1,1) 5,9 (1,3) 0.01 0.03 1,0 (0,7-1,4) 0,7 1,2 (0,7-1,7) 0,8
SF-36:
Physical functioning 82,8 (17,4) 85,8 (16,5) 91,8 (12,4) 0,02 0,67 3,0 (-2,3- 8,3) 0,2 8,2 (3,7-12,8) 0,5
Role physical 40,2 (42,6) 63,5 (44,9) 80,6 (34,1) 0,01 0,69 23,4 (8,3-38,4) 0,6 37,8 (22,8-52,8) 0,9
Bodily pain 51,4 (25,7) 72,2 (26,9) 80,0 (22,7) 0,01 0,09 20,8 (12,5- 29,1) 0,8 30,2 (21,0- 39,4) 1.1
General health 48,2 (17,2) 53,5 (20,5) 61,3 (19,4) 0,01 0,89 5,4 (0,9-9,8) 0,3 12,8 (7,7-18,0) 0,7
Vitality 46,6 (23,9) 58,7 (24,1) 66,0 (20,2) 0,01 0,43 12,1 (4,5-19,6) 0,5 18,5 (11,2-25,8) 0,8
Social functioning 71,3 (23,6) 82,6 (20,1) 89,4 (19,9) 0,01 0,50 11,3 (4,3-18,2) 0,5 19,4 (11,3-27,6) 0,8
Role emotional 63,4 (43,3) 83,8 (33,6) 80,4 (36,1) 0,02 0,09 20,4 (8,0-32,7) 0,5 14,4 (-0,01-29,0) 0,3
Mental health 59,6 (19,7) 73,5 (16,9) 76,5 (17,6) 0,01 0,05 13,9 (8,5-19,4) 0,71 14,7 (9,6-19,9) 0,75
(*) Holm-Bonferroni corrected. L = linear, Q = quadratic, ES = effect size.
Table 4 Health-related quality of life at baseline, six and at 12 months in ulcerative colitis patients.
Basal 6
th month 12
th month Trend p values (*) Differences 0 and 6
th month Differences 0 and 12
th month
Mean (SD) Mean (SD) Mean (SD) L Q Mean (CI 95%) ES Mean (CI 95%) ES
IBDQ:
Bowel 4,6 (1,4) 5,3(1,6) 5,3 (1,3) 0,14 0,73 0,8 (0,1 - 1,5) 0,4 1,0 (-0,01 - 2,0) 0,7
Systemic 4,1 (1,5) 4,8 (1,5) 4,8 (1,2) 0,66 0,06 0,7 (-0,2 - 1,6) 0,5 0,8 (-0,1 - 1,8) 0,5
Emotional 4,5 (1,6) 5,1 (1,6) 5,3 (1,3) 0,21 0,92 0,5 (-0,3 -1,3) 0,3 0,9 (0,01 -1,7) 0,6
Social 4,1 (2,1) 5,3 (2,0) 6,0 (1,4) 0,02 0,59 1,2 (0,2- 2,3) 0,6 1,7 (0,6 - 2,9) 0,8
Functional 3,9 (1,7) 5,0 (1,8) 5,2 (1,3) 0.08 0.33 1,1 (0,2 - 2,0) 0,7 1,2 (0,3 - 2,1) 0,7
SF-36:
Physical functioning 70,7 (25,1) 76,4 (22,6) 83,2 (18,1) 0,08 0,84 5,7 (-1,3 - 12,8) 0,2 10,4 (1,2 - 19,5) 0,4
Role physical 41,7 (44,3) 53,6 (46,3) 59,4 (38,7) 0,29 0,79 11,9 (-11,6 -35) 0,3 23,7 (-8,2 - 55,6) 0,5
Bodily pain 52,1 (28,6) 56,4 (27,8) 57,7 (20,5) 0,28 0,11 14,3 (0,6- 28,0) 0.5 10,8 (-3,4 - 25,0) 0,4
General health 41,3 (18,4) 46,0 (19,5) 50,8 (23,8) 0,14 0,60 4,7 (-3,3 - 12,6) 0,3 8,5 (-5,8 - 22,7) 0,5
Vitality 47,1 (21,2) 52,1 (25,5) 59,4 (21,8) 0,07 0,78,0,80 5,0 (-6,3 - 16,0) 0,2 16,5 (0,2 - 32,7) 0,8
Social functioning 61,3 (28,2) 73,2 (28,9) 81,6 (17,4) 0,08 0,64 11,9 (-2,1 - 26) 0,4 20,9 (2,5 - 39,2) 0,5
Role emotional 61,9 (46,3) 71,4 (38,4) 76,5 (33,1) 0,63 0,66 9,5 (-14,5 -34) 0,2 19,4 (-13,1 - 51,9) 0,4
Mental health 54,7 (22,1) 61,7 (21,9) 72,2 (20,3) 0,02 7,0 (-2,4-16,5) 0,3 15,4 (0,5 - 30,2) 0,7
(*) Holm-Bonferroni corrected. L = linear, Q = quadratic, SE = effect size.
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of recurrence. The ΔIBDQ had a good correlation with
CDAI (r = -0.38, P = 0.002). Conversely, those patients
treated with infliximab or with systemic steroids at base-
line experienced a significantly greater improvement in
ΔIBDQ. In UC patients, only tobacco smoking was
related to the ΔIBDQ. In order to exclude confounding
variables, regression analysis of clinical variables was
performed. In UC patients, the ΔIBDQ was associated
with tobacco smoking, and patients who smoked had
small ΔIBDQs compared with never or ex-smokers. No
variables were found to be associated with ΔIBDQ in
CD patients.
Twelve-month Assessment
Seventy-four patients reached 12 months of follow up.
Of them, 10 patients were lost, thus only 64 patients
were able to complete the questionnaires. At this point,
45 patients–61% as per intention to treat and 70% per
protocol–were in clinical remission and free of steroids.
Median global IBDQ scores were 6.1 (SD 1.14; range
2.7-6.98). Compared with baseline, 47 (64%) patients’
scores improved: the median ΔIBDQ was 1.05 (SD 1.28;
range -2.2 to 3.7) and the effect size of the difference
was 0.83.
Tables 3 and 4 give the comparisons of the IBDQ and
SF-36 scores of patients at enrollment and after 12
months of treatment.
After one year of treatment with thiopurines, all the
dimensions of the specific IBDQ and generic SF-36
questionnaires improved significantly compared with
baseline and all the scores was higher than those
obtained at six months. Only the scores of the SF-36
physical functioning and mental health were equal to
the general Spanish population, with the remaining
dimensions slightly worse than the reference values
(Fig. 1). The gaining in SF-36 was indepedent of gender
in all domains.
The ΔIBDQ at 12 months was correlated with the
number of previous admissions in both CD (r = 0.58,
P =0 . 0 4 7 )a n dU C( r=0 . 3 0 ,P = 0.029) patients. Addi-
tionally, in those patients with CD, the improvement
was significantly greater in those patients treated with
steroids at the beginning of treatment. In UC patients,
the gain was significantly higher in those for whom the
indication of treatment was maintenance after a severe
flare or induction of remission. Other clinical variables
studied were not related to the ΔIBDQ. Regression ana-
lysis confirmed that the improvement in HRQoL in CD
patients correlated only with steroid use at the begin-
ning of treatment and this association was independent
of the indication and other concomitant treatments. For
UC patients, no association was seen in the multivariate
analysis.
Discussion
Our study shows that before initiating thiopurines,
patients with IBD have greatly impaired perceived health
status involving the majority of the aspects of HRQoL.
Figure 1 SF-36 mean scale scores of Crohn’s disease and ulcerative colitis patients in comparison to Spanish general population
reference values. PF: Physical Functioning, RP: Role physical, BP: Bodily Pain, GH: General health, VT: Vitality, SF: Social functioning, RE: Role
emotional, MH: Mental health.
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evidence of the positive and long-lasting impact of
azathioprine and 6-mercaptopurine on all dimensions of
HRQoL in patients with IBD.
Currently, thiopurines are the cornerstone of the treat-
ment of IBD patients and are used in several clinical
situations [42]. The first issue addressed in this study was
the pattern of HRQoL in patients before starting thiopur-
ines. As expected, this group of patients had impaired
HRQoL. The mean scores in the eight domains of the SF
36 were all lower than published Spanish reference data
[34]. The physical function domain gave the worst scores:
this dimension includes items that assess whether the
patient has problems with work or other daily activities
because of their physical health. It is well recognized that
remission is associated with increased employment and
productivity in both UC and CD [43,44]. Therefore,
restoring the physical role and thus the availability to
work is an important indirect endpoint.
The pattern of impaired dimensions in the IBDQ-36
showed that the bowel symptoms score was the least
impaired at the beginning of treatment. Conversely, the
largest impact appeared to be in the systemic domain.
This pattern is different to previously published data
from patients with active or inactive disease in which
bowel symptoms was the worst scored domain in active
disease patients and systemic symptoms the most
affected domain in patients in remission [6]. These
divergences can be attributed to the use of steroids and
other drugs that could be able to ameliorate bowel
symptoms but are not able to restore completely the
quality of life of patients, probably because nonspecific
symptoms such as fatigue, general discomfort, sleep dis-
turbances and appetite problems are still present. The
association of the use of steroids with a worse HRQoL
in patients with CD supports this proposed explanation.
Other authors have already suggested this association
[45]. Recently, in a study performed with UC patients
treated with infliximab, those patients who had discon-
tinued corticosteroid use showed greater improvement
in HRQoL than those who had not [22]. This interesting
finding is relevant and reinforces the idea that a patient
receiving steroids should not be considered in remission.
The second issue addressed, and which produced our
main finding, was to provide evidence that thiopurine
treatment has a positive effect on all dimensions of
HRQoL. More importantly, this effect is durable, with
better scores after one year of treatment than at six
months. Few data are available with which to compare
our results. One case-control study reported that a sus-
tained response to thiopurine immunomodulators
restores HRQoL and psychological well-being in patients
with CD to values equivalent to those of healthy con-
trols [29].
Globally, results obtained with the specific question-
naire for both CD and UC at six and 12 months showed
an effect size larger than 0.5 in all dimensions studied,
meaning that the magnitude of improvement in HRQoL
is definitely relevant. It is important to remark that the
interpretation of HRQoL scores could be complex. The
interpretation could be based on the statistical signifi-
cance of a change, but placing the magnitude of these
changes in a context easy to understand is arduous. To
provide meaningful interpretation of HRQoL interven-
tion and treatment effects two broad strategies have
been described: the effect size and the minimum clini-
cally important difference. In our paper to facilitate the
interpretation of the scores the changes are expressed in
both [46]. HRQoL was slightly worse in UC than in CD
patients throughout the study and the improvement
seen during the study was lower in UC patients. Only
the social impairment dimension (avoiding events if toi-
lets are not nearby, canceling social engagements), the
most affected difference at the beginning of treatment,
showed a greater improvement in UC patients. This
observation differs from previously published data
because UC patients typically experience better HRQoL
than those with CD [4-6]. It is difficult to speculate
about this finding mainly because the available evidence
suggests that thiopurine therapy is as effective in UC as
it is in CD [12]. A possible explanation for our findings
is that the patients with UC were all patients with severe
disease, while many patients with CD were not, and
those patients treated with thiopurines to prevent post-
surgical recurrence and thus with inactive disease could
exemplify this hypothesis.
Globally, the SF-36 showed homogeneous improve-
ment in all dimensions, although complete restoration
of HRQoL was not achieved, probably because IBD
patients have a worse HRQoL despite having inactive
disease. The magnitude of improvement was greater
than the minimum important difference in all domains
except general health at both at six and 12 months and
physical functioning at six months. The effect size also
showed a relevant improvement, mainly after one year
of treatment. Two considerations merit comment about
the SF-36 results. First, the general health dimension
(considered as an indicator of patients general health)
had an increase relatively small in contrast to much
greater differences of many other dimensions, one expla-
nation is that thiopurines need periodical clinical moni-
t o r i n ga n dm a yp r o d u c es e v e r es i d ee f f e c t st h a tc o u l d
decrease HRQoL. Second, there was a trend toward bet-
ter results in the mental health-related domains in UC
patients while CD patients obtained better results in the
physical health domains. One explanation for this find-
ing is that patients with UC had less disease duration,
probably some factors that affected HRQOL could vary
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have published that duration of disease influences the
emotional domain: the longer time with UC the better
emotional well-being, suggesting a degree of adjustment
over time to their condition [47].
Conclusions
Some considerations should be taken into account
before extracting conclusions. First, this is a prospective
study, thus behavior of different dimensions of HRQoL
during follow up can be seen. Additionally the study has
a follow-up period of one year, and probably at the end
of the study the initial contribution of other medications
as steroids, Infliximab or Cyclosporine is not present.
Additionally the length of the study allows to identify
those side effects that could only be detected after the
first months and that may possibly affect the HRQoL.
The cohort was included prospectively and consecutively
and the study was performed in clinical practice condi-
tions, thus both CD and UC were considered along with
all types of scenario where thiopurines are used. We
found a significant improvement in all indications
including the prevention of postoperative recurrence.
This fact could be explained by several reasons. The
patients were included one year after the surgery when
endoscopic recurrence was established; although they
were inactive at inclusion, they had symptoms that were
probably affecting their HRQoL. We think that those
symptoms could be caused by the endoscopic recur-
rence and therefore the healing of lesions induced by
the azathioprine, possibly will be the cause of the
improvement in the HRQoL.
Future investigations should assess the long-term
impact on HRQoL of new scenarios in which thiopur-
ines are currently used, such as early introduction in
both UC and CD. In this study, we did not routinely
perform endoscopy. Another important issue that
should be addressed in future investigations is the impli-
cations on HRQoL and in the natural history of
azathioprine-induced mucosal healing.
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